Report Sections

See All Reports

  • HP:0001264: Spastic diplegia
  • Pneumonia (359) Respiratory tract infection (38) Neoplasm (36) Abnormality of the cardiovascular system (34) Diabetes mellitus (33) Depressivity (29) Acute kidney injury (27) Hypoxemia (26) Hypertension (24) Abnormal lung morphology (24) Thromboembolism (22) Anosmia (20) Myocardial infarction (20) Arthritis (19) Type II diabetes mellitus (18) Stroke (16) Pulmonary embolism (16) Mental deterioration (15) Abnormality of coagulation (15) Pulmonary fibrosis (15) Chronic pulmonary obstruction (15) Abnormality of the kidney (14) Autistic behavior (14) Rheumatoid arthritis (14) Leukemia (14) Interstitial pneumonitis (14) Pulmonary obstruction (14) Asthma (13) Chronic pain (13) Congestive heart failure (12) Deep venous thrombosis (12) Neoplasm of the lung (12) Autism (11) Obesity (11) Respiratory distress (11) Colitis (11) Ulcerative colitis (11) Crohn's disease (11) Type I diabetes mellitus (10) Abnormality of the liver (9) Coronary artery atherosclerosis (9) Inflammation of the large intestine (9) Pulmonary insufficiency (9) Chronic kidney disease (9) Myocarditis (9) Behavioral abnormality (8) Psychosis (8) Dementia (8) Alzheimer disease (8) Carcinoma (8) Low levels of vitamin D (8) Sepsis (8) Infertility (7) Peripheral arterial stenosis (7) Renal insufficiency (6) Lymphopenia (6) Dysphagia (6) Lymphoma (6) Systemic lupus erythematosus (6) Osteoarthritis (6) Breast carcinoma (6) Psoriasiform dermatitis (6) Abnormality of the gastrointestinal tract (6) Fatigue (6) Encephalopathy (5) Premature birth (5) Bronchiectasis (5) Difficulty walking (5) Gastroparesis (5) Immunodeficiency (5) Obstructive sleep apnea (5) Autoimmunity (5) Knee osteoarthritis (5) Sleep apnea (5) Prostate cancer (5) Allergy (5) Non-small cell lung carcinoma (5) Schizophrenia (5) Neoplasm of the large intestine (5) Seizure (4) Hepatic fibrosis (4) Cardiac arrest (4) Weight loss (4) Migraine (4) Pulmonary arterial hypertension (4) Abnormal intestine morphology (4) Neoplasm of the pancreas (4) Colon cancer (4) Malnutrition (4) Paroxysmal atrial fibrillation (4) Disseminated intravascular coagulation (4) Attention deficit hyperactivity disorder (4) Inflammatory abnormality of the skin (4) Neoplasm of head and neck (4) Endometriosis (4) Addictive behavior (4) Hypercoagulability (4) Insomnia (4) Obsessive-compulsive behavior (3) Eczema (3) Atopic dermatitis (3) Spastic diplegia (3) Abnormal heart morphology (3) Cardiomyopathy (3) Fever (3) Hypothermia (3) Headache (3) Celiac disease (3) Reduced factor VIII activity (3) Lymphoid leukemia (3) Renal cell carcinoma (3) Abnormal anterior horn cell morphology (3) Amyotrophic lateral sclerosis (3) Cystoid macular edema (3) Arrhythmia (3) Cutaneous melanoma (3) Pulmonary edema (3) Ovarian neoplasm (3) Neuroendocrine neoplasm (3) Hypogeusia (2) Hearing impairment (2) Abnormality of the eye (2) Visual impairment (2) Conjunctivitis (2) Cataract (2) Uveitis (2) Agoraphobia (2) Abnormality of the endocrine system (2) Abnormality of the skin (2) Jaundice (2) Lymphedema (2) Spasticity (2) Meningitis (2) Abnormal joint morphology (2) Hepatic steatosis (2) Hepatic failure (2) Tachycardia (2) Angina pectoris (2) Pancreatitis (2) Abnormality of blood and blood-forming tissues (2) Thrombocytopenia (2) Autoimmune thrombocytopenia (2) Gout (2) Diarrhea (2) Gastroesophageal reflux (2) Apnea (2) Neurodegeneration (2) Alopecia of scalp (2) Mutism (2) Transient ischemic attack (2) Hyperkinetic movements (2) Polyphagia (2) Hypotension (2) Atherosclerosis (2) Hypoventilation (2) Squamous cell carcinoma (2) Myelodysplasia (2) Back pain (2) Low back pain (2) Muscular dystrophy (2) Stillbirth (2) Acute myeloid leukemia (2) Lymphoproliferative disorder (2) Myeloproliferative disorder (2) Multiple myeloma (2) Intervertebral disc degeneration (2) Stridor (2) Postprandial hyperglycemia (2) Hemeralopia (2) Arteritis (2) Hepatitis (2) Glioblastoma multiforme (2) Cervix cancer (2) Small cell lung carcinoma (2) Endocarditis (2) Toxemia of pregnancy (2) Myositis (2) Mania (2) Urinary retention (1) Urinary incontinence (1) Nephritis (1) Menorrhagia (1) Xerostomia (1) Otitis media (1) Conductive hearing impairment (1) Amblyopia (1) Periodontitis (1) IgA deposition in the glomerulus (1) Enuresis (1) Hypoparathyroidism (1) Adrenal insufficiency (1) Hyperaldosteronism (1) Osteopenia (1) Urticaria (1) Angiokeratoma corporis diffusum (1) Cholecystitis (1) Keratoconjunctivitis (1) Intellectual disability (1) Hemiparesis (1) Polyneuropathy (1) Syncope (1) Cerebral hemorrhage (1) Hepatocellular carcinoma (1) Intrauterine growth retardation (1) Hoarse voice (1) Dysphonia (1) Weak voice (1) Sudden cardiac death (1) Aortic valve stenosis (1) Bradycardia (1) Torsade de pointes (1) Atrioventricular block (1) Premature rupture of membranes (1) Dehydration (1) Constipation (1) Anorexia (1) Esophageal varix (1) Chorea (1) Status epilepticus (1) Subarachnoid hemorrhage (1) Abnormality of the spinal cord (1) Memory impairment (1) Encephalitis (1) Spina bifida (1) Language impairment (1) Waddling gait (1) Increased intracranial pressure (1) Biliary cirrhosis (1) Dilatation (1) Osteomyelitis (1) Central apnea (1) Hypokalemia (1) Hyponatremia (1) Hyperphosphatemia (1) Skeletal muscle atrophy (1) Male infertility (1) Spondylolisthesis (1) Myalgia (1) Bruxism (1) Neonatal death (1) Increased body weight (1) Intermittent claudication (1) Thrombophlebitis (1) Chronic bronchitis (1) Ventricular tachycardia (1) Acute myelomonocytic leukemia (1) Dilatation of the cerebral artery (1) Coronary artery stenosis (1) Venous insufficiency (1) Chronic lymphatic leukemia (1) Abnormality of bone marrow cell morphology (1) Hypersensitivity pneumonitis (1) Intraalveolar phospholipid accumulation (1) Neoplasm of the genitourinary tract (1) Neoplasm of the skin (1) Female infertility (1) Benign prostatic hyperplasia (1) Hip osteoarthritis (1) Bladder neoplasm (1) Stomatitis (1) Uterine neoplasm (1) Intestinal atresia (1) Placental abruption (1) Sinus tachycardia (1) Bronchiolitis (1) Erythroid hypoplasia (1) Asterixis (1) Hodgkin lymphoma (1) B-cell lymphoma (1) Ciliary dyskinesia (1) Myeloid leukemia (1) Chronic myelomonocytic leukemia (1) Morphea (1) Bronchitis (1) Hypercapnia (1) Pain (1) Retinal vein occlusion (1) Vasovagal syncope (1) Heart block (1) Cough (1) Neonatal asphyxia (1) Dyspareunia (1) Heart murmur (1) Cardiogenic shock (1) Cholangitis (1) Cholangiocarcinoma (1) Vulvar neoplasm (1) Neonatal sepsis (1) Glue ear (1) Abnormality of movement (1) Subdural hemorrhage (1) Biliary tract neoplasm (1) Nasal polyposis (1) Eclampsia (1) Esophagitis (1) Vaginal neoplasm (1) Cellulitis (1) Angioedema (1) Self-injurious behavior (1) Gastrointestinal stroma tumor (1) Bulimia (1) Neoplasm of the rectum (1) Chest pain (1) Atelectasis (1) Lymphocytosis (1) Polymenorrhea (1)

    HP:0001264: Spastic diplegia

    Developed by Shray Alag, The Harker School
    Sections: Correlations, Clinical Trials, and HPO

    Correlations computed by analyzing all clinical trials.

    Navigate: Clinical Trials and HPO

    Correlated Drug Terms (7)

    Name (Synonyms) Correlation
    drug4466 eM2M Wiki 0.58
    drug947 Co-created intervention Wiki 0.58
    drug1094 Covid-19 + patients Wiki 0.58
    Name (Synonyms) Correlation
    drug1223 Difficulties lived by disabled children's parents in the period of COVID-19 pandemic Wiki 0.58
    drug1092 Covax-19™ Wiki 0.58
    drug912 Chloroquine phosphate Wiki 0.33
    drug3928 Telemedicine Wiki 0.29

    Correlated MeSH Terms (9)

    Name (Synonyms) Correlation
    D002547 Cerebral Palsy NIH 1.00
    D016135 Spinal Dysraphism NIH 0.58
    D009136 Muscular Dystrophies NIH 0.41
    Name (Synonyms) Correlation
    D013119 Spinal Cord Injuries NIH 0.22
    D000070642 Brain Injuries, Traumatic NIH 0.19
    D010300 Parkinsonian NIH 0.19
    D001930 Brain Injuries, NIH 0.16
    D009103 Multiple Sclerosis NIH 0.14
    D014947 Wounds and Injuries NIH 0.10

    Correlated HPO Terms (2)

    Name (Synonyms) Correlation
    HP:0002414 Spina bifida HPO 0.58
    HP:0003560 Muscular dystrophy HPO 0.41

    Clinical Trials

    Navigate: Correlations   HPO

    There are 3 clinical trials

    1 The M2M LEADERS Project: Lakeshore Examination of Activity, Disability, and Exercise Response Study (LEADERS)

    The purpose of this study is to test the effects of an innovative exercise program referred to as movement-2-music (M2M) on health and fitness outcomes in adults with physical/mobility disabilities. One hundred and eight participants with physical/mobility disabilities will be recruited and randomly enrolled into one of two groups: a) M2M or b) waitlist control. The primary aim of this study is to determine the effects of a 12-week M2M program on health and fitness in participants with physical/mobility disabilities who are in one of three functional mobility groups: 1) Group I - only able to exercise while sitting, 2) Group II - able to exercise sitting and standing with/without support, and 3) Group III - able to exercise one side of the body more than the other side. The second aim is to compare the observed effects of the program in this study to a previous M2M study that groups participants based on disability type. The third aim of this study is to test whether adherence (defined as attendance to the 12-week program) affects the effects of M2M in participants with physical/mobility disabilities. The potential influences of different functional mobility and disabilities of participants on how the program affects participants' health and fitness outcomes will also be tested. **In response to COVID-19, the 12-week M2M intervention and all assessments have been modified from being delivered in-person at Lakeshore Foundation to being delivered remotely in real-time through videoconferencing technology.**

    1. Spinal Cord Injuries
    2. Traumatic Brain Injury
    3. Spina Bifida
    4. Cerebral Palsy
    5. Stroke
    6. Parkinson Disease
    7. Multiple Sclerosis
    1. Other: eM2M
    MeSH:Parkinson Disease Multiple Sclerosis Brain Injuries Spinal Cord Injuries Brain Injuries, Traumatic Cerebral Palsy Spinal Dysraphism Wounds and Injuries
    HPO:Athetoid cerebral palsy Cerebral palsy Spastic diplegia Spina bifida

    Primary Outcomes

    Description: The cardiorespiratory fitness is measured using a heart rate recovery test

    Measure: Change from baseline cardiorespiratory fitness at 3 months

    Time: Baseline and post 12-week intervention

    Description: Muscle strength is measured with grip strength using a hand-held dynamometer.

    Measure: Change from baseline muscle strength at 3 months

    Time: Baseline and post 12-week intervention

    Secondary Outcomes

    Description: Lower extremity function is assessed using the Short Physical Performance Battery (SPPB)

    Measure: Change from baseline lower extremity function at 3 months

    Time: Baseline and post 12-week intervention

    Description: Lower extremity function will be assessed using the Timed Up and Go (TUG) test.

    Measure: Change from baseline lower extremity function at 3 months

    Time: Baseline and post 12-week intervention

    Description: Health-related quality of life is measured using the National Institutes of Health Patient-Reported Outcomes Measurement Information System (PROMIS) Global-10 Health Items. The instrument is a 10-item measure with the response scores ranging from 1 (very severe) to 5 (none). Two summary scores, a global physical health score and a global mental health score, can be calculated from this scale, with each score ranging from 4 to 20. Higher scores indicate better health. The total raw score is translated into a T-score for each participant for analysis.

    Measure: Change from baseline health-related quality of life at 3 months

    Time: Baseline and post 12-week intervention

    Description: Social participation is measured using the National Institutes of Health Patient-Reported Outcomes Measurement Information System (PROMIS) Ability to Participate in Social Roles and Activities. The instrument is a 8-item measure with the response scores ranging from 1 (always) to 5 (never). The lowest possible total raw score is 8 and the highest possible score is 40. Higher scores indicate better ability to participate in social roles and activities. The total raw score is translated into a T-score for each participant for analysis.

    Measure: Change from baseline social participation at 3 months

    Time: Baseline and post 12-week intervention

    Description: Physical activity is measured using the Godin Leisure Time Exercise Questionnaire. The questionnaire contains two questions. The first question asks participants to report weekly frequencies of activities they perform at different intensities. A total weekly leisure activity is a sum of activity scores calculated by multiplying the weekly frequencies of strenuous, moderate, and light activities by 9, 5, and 3, respectively. The second question asks participants the frequency of weekly leisure-time activities performed that are long enough to work up a sweat.

    Measure: Change from baseline physical activity at 3 months

    Time: Baseline and post 12-week intervention

    Other Outcomes

    Description: Barriers in physical activity will be assessed using the Barriers in Physical Activity Questionnaire. The instrument contains 43 items. Each item is responded with either no (1) or yes (2). If response is yes, a follow-up response that ranges from 1 (very small) to 5 (very large) is selected. There are 8 domains, which include personal health, attitudes/beliefs towards physical activity, friends, family, fitness center built environment, policy/programs/staff, community built environment, and safety. Each domain score is calculated by summing the item responses with its respective item weight. Higher domain scores indicate greater perceived barriers to physical activity.

    Measure: Change from baseline barriers in physical activity at 3 months

    Time: Baseline and post 12-week intervention

    Description: Exercise self-efficacy will be assessed using the Exercise Self-Efficacy Scale. The scale contains 8 items, with response options of each item ranging from 0% (not at all confident) to 100% (highly confident). All items are summed and a mean score is calculated. Higher scores indicate higher levels of self-efficacy.

    Measure: Change from baseline exercise self-efficacy at 3 months

    Time: Baseline and post 12-week intervention

    Description: Exercise goal-setting will be measured using the Exercise Goal-Setting Scale. The instrument contains 10 items with response options ranging from 1 (does not describe) to 5 (describes completely). A mean score is calculated. A higher mean score indicate better goal-setting and self-monitoring for exercise.

    Measure: Change from baseline exercise goal-setting at 3 months

    Time: Baseline and post 12-week intervention

    Description: Outcome expectations for exercise will be assessed using the Multidimensional Outcome Expectations for Exercise Scale. The instrument contains 15 items, with the response options ranging from 1 (strongly disagree) to 5 (strongly agree). Three domains of outcome expectations for exercise are assessed, which include physical outcome expectations (6 items), social outcome expectations (4 items), and self-evaluative outcome expectations (5 items). Each dimension is scored by summing the item responses. Higher scores indicate higher levels of outcome expectations for exercise.

    Measure: Change from baseline outcome expectations for exercise at 3 months

    Time: Baseline and post 12-week intervention

    Description: Social support will be assessed using the Social Provision Scale. The instrument contains 24 items, with the response options ranging from 1 (strongly disagree) to 4 (strongly agree). A total score is calculated by summing scores from all items. A higher score indicates a greater degree of perceived support.

    Measure: Change from baseline social support at 3 months

    Time: Baseline and post 12-week intervention
    2 Pain and Pain Burden in Children and Adolescents With Cerebral Palsy - the CPPain Program

    Pain in children and adolescents with cerebral palsy (CP) is a significant health challenge that so far has received too little attention. We lack knowledge on how pain is experienced, its consequences and of perceived support in managing pain. The overarching aim of the CPPain-program is to reduce pain experience, pain interference (e.g. pain burden) in children and adolescents living with CP. CPPain has a prospective cohort comparative design and will include before- and after measurements and process evaluation of a nested intervention. This protocol concerns qualitative and quantitative data collection for the baseline of the CPPain program. The aim of the baseline data collection is to contribute in-depth knowledge of the pain burden in children and adolescents with CP. This knowledge is required to develop targeted pain-diminishing interventions in this vulnerable group of children with a high burden of challenges related to their chronic disease. In the next step, nested intervention will be co-created with children and adolescents with CP, their parents as well as health care professionals, and other professional caregivers involved in or responsible for management of pain based on existing research and baseline findings.

    1. Cerebral Palsy
    1. Other: Co-created intervention
    MeSH:Cerebral Palsy
    HPO:Athetoid cerebral palsy Cerebral palsy Spastic diplegia

    Primary Outcomes

    Description: Measured with a modified version of the Brief Pain Inventory (BPI) (Engel, 2009). mBPI has 12 items scored from 0 to 10 points, giving a total score ranging from 0 to 120 points where zero means that pain does not interfere with function while higher scores indicate a more negative outcome (higher pain interference)

    Measure: Pain interference

    Time: 3 years
    3 COVID-19 Pandemic From the Perspective of Parents of Disabled Children

    Pandemic period could affect the disabled children's rehabilitation and follow-up negatively because of preventive measures and this could create adverse results on their parents. In this research, it is aimed to determine the positive and negative effects of pandemic on parents and disabled children and to provide an insight for future solutions.

    1. COVID-19
    2. Disabilities Multiple
    3. Cerebral Palsy
    4. Muscular Dystrophies
    1. Other: Difficulties lived by disabled children's parents in the period of COVID-19 pandemic
    MeSH:Muscular Dystrophies Cerebral Palsy
    HPO:Athetoid cerebral palsy Cerebral palsy Muscular dystrophy Spastic diplegia

    Primary Outcomes

    Description: Difficulties related to rehabilitation facilities, other medical conditions or ortosis could increase because of Covid 19 pandemic unique conditions

    Measure: A questionnaire that we created will be used to determine the difficulties experienced by disabled children's parents during Covid 19 pandemic related to their medical follow-up

    Time: 4 weeks

    Secondary Outcomes

    Description: The Fear of COVID-19 Scale, a seven-item scale, has robust psychometric properties. It is reliable and valid in assessing fear of COVID-19 among the general population and will also be useful in allaying COVID-19 fears among individuals. Score is minimum 7 pointts and maximum 35 points.

    Measure: The Fear of COVID-19 Scale

    Time: 4 weeks

    HPO Nodes


    Data processed on September 26, 2020.

    An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.

    Drug Reports   MeSH Reports   HPO Reports  


    4,180 reports on interventions/drugs


    691 reports on MeSH terms


    263 reports on HPO terms

    All Terms

    Alphabetical index of all Terms

    Google Colab

    Python example via Google Colab Notebook